MA-BATTERY-VENTURES
Battery Ventures, a global, technology-focused investment firm, today announced six new internal promotions across three offices, including the elevation of Satoshi Harris-Koizumi to partner and Collier Searle to principal.
Harris-Koizumi is based in New York and focuses on later-stage and majority software investments, mainly in the U.S. Since joining Battery 12 years ago, he has supported technology companies transforming industries ranging from hospitality to manufacturing to engineering and supply chain, among others.
Specifically, Harris-Koizumi has worked with exited Battery software companies Cambrio (a CAD/CAM specialist, acquired by Sandvik); HighJump (supply-chain tech, acquired by Accellos); Mendix (low-code platform technology, acquired by Siemens); and Olo (restaurant-ordering software, NYSE: OLO). He is currently involved with Battery’s investments in product-content software company 1WorldSync; developer-tools software firm AdaCore; club/member-management software company Clubessential Holdings; restaurant-software provider Crunchtime; translation-software company Smartling; and engineering-design software firm Tech Soft 3D. Harris-Koizumi, known as Toshi, holds a BA in economics from Dartmouth.
Searle, also based in New York, joined Battery in 2020 and focuses on late-stage and buyout investments in Europe and the U.S. She is involved with Battery’s investments in ORTEC, a company based in the Netherlands which provides decision-support software and data-science capabilities, and Shiftmove, a Berlin-based company providing “mobility-management” solutions to enterprises. Battery formed Shiftmove last year after acquiring two complementary, European fleet-management companies, Vimcar and Avrios. Before Battery, Searle worked at Apax Partners and Bank of America Merrill Lynch. She holds a BA in philosophy and political science from Middlebury.
“We are extremely excited to promote Toshi to partner and Collier to principal,” said Morad Elhafed, a Battery general partner who works closely with both investors. “Toshi has distinguished himself both by sourcing key deals for the firm—including Cambrio, Clubessential, Mendix and Tech Soft—and, later, serving as a trusted advisor to our portfolio executives and helping their companies scale. Similarly, Collier has done outstanding sourcing and advisory work, particularly as we increase our buyout activity in Europe. We are excited for both of them to continue their careers at Battery and add more value to the firm as we move into our fifth decade of investing.”
Battery also named two new vice presidents, Max Jessen and Stefan Momic, and two new associates, Jack McGuinness and Grace Hermes. Jessen and Momic are both based in Boston and work in Battery’s growing industrial technology and life-science tools practice. McGuinness, based in London, also focuses on industrial technology and life-science tools, while Hermes works in Battery’s New York office and focuses on later-stage software investments.
Earlier this year, Battery also announced the promotions of Aaron Neil to vice president and Luis-Luca de Haas to associate. In addition, Matt Penney was promoted to partner, information technology.
Battery Ventures provides investment advisory services solely to privately offered funds. Battery Ventures neither solicits nor makes its services available to the public or other advisory clients. For more information about Battery Ventures’ potential financing capabilities for prospective portfolio companies, please refer to our website. For a complete list of portfolio companies, please click here.
About Battery
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer tech, healthcare IT and industrial technology and life-science tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, New York, London, and Tel Aviv. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627095034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom